LPAAU — Launch One Acquisition Corp.
—
Nasdaq ·
Financials ·
Diversified Financial Services ·
CIK 2015502 ·
Last close
$10.74
Market Cap
$247.02M
52W High
$10.94
52W Low
$10.74
ADV30
7
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -467,775 | 1,700,072 | 248,069,099 | 266,001 | 12,479,635 |
| Dec 2025 | 0 | — | -277,941 | 2,088,681 | 245,630,529 | 30,146 | 11,741,137 |
| Sep 2025 | 0 | — | -517,261 | 2,011,042 | 243,472,003 | 97,652 | 11,671,292 |
| Jun 2025 | 0 | — | -637,837 | 1,922,018 | 241,152,118 | 263,740 | 11,362,449 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-820,192
Investing CF
$0
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-11,560,536
Inventory
—
Receivables
$28,590
ST Investments
—
EBIT TTM
$-1,611,081
Pretax Income TTM
$8,309,154
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,611,081 | 8,309,154 | 245,630,529 | 11,741,137 | — | -820,192 |
| Dec 2024 | 0 | -400,002 | 5,129,519 | 236,639,418 | 11,059,180 | — | -472,305 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XRPN | Armada Acquisition Corp. II | $246.58M | $10.40 | — |
| RAC | Rithm Acquisition Corp. | $246.54M | $10.42 | — |
| LPAA | Launch One Acquisition Corp. | $247.71M | $10.77 | — |
| SAAQ | Space Asset Acquisition Corp. | $246.14M | $10.41 | — |
| LPBB | Launch Two Acquisition Corp. | $245.87M | $10.69 | — |
News headlines (Yahoo Finance, 1h cache)
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
2026-01-13 15:15 · Yahoo
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
2025-10-15 11:30 · Yahoo
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
2025-09-18 11:30 · Yahoo
Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers
2025-08-27 11:15 · Yahoo
Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth
2025-07-24 12:15 · Yahoo
Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome
2025-06-30 12:30 · Yahoo
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Mark
2025-06-25 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.